Dr. Apter is now visiting 30th ECNP Congress in Paris
The 30th ECNP Congress for disease-oriented brain research is ongoing in Paris. Schizophrenia, depression, neuronal autophagy, new findings in applied neuroscience research are certainly not all the topics of the event agenda.
European College of Neuropsychopharmacology is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health. ECNP sets goals to support innovative research in neuropsychopharmacology and facilitate sharing of ideas, discoveries and best practices.
Operating in 8 countries in Eastern Europe as well as in India and led by a management team with 50+ years of combined clinical trials experience, GCT has gained an impressive background of numerous successfully completed clinical studies in CNS.
GCT President Dr. Jeffrey Apter, Principal Investigator in over 100 trials in Depression, Anxiety, Bipolar Disorder, Schizophrenia and Alzheimer’s Disease, has only several free timeslots to meet at the ECNP Congress tomorrow and discuss face-to-face the arising trends in the clinical trial industry in the Eastern Europe and India. To schedule a meeting, please urgently contact email@example.com.
Updated: September 4, 2017
Permanent link: https://2022.gctrials.com/posts/dr-apter-is-now-visiting-30th-ecnp-congress-in-paris/